source
- FDA approves Emcitate for peripheral thyrotoxicosis in patients with MCT8 deficiencyThe U.S. Food and Drug Administration announced approval of Emcitate (tiratricol) tablets formulated for oral suspension to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, also ca…
- FDA grants accelerated approval for Etcamah combo therapy for advanced HR-positive, HER2-negative breast cancerThe U.S. Food and Drug Administration announced accelerated approval of Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adult patients with hormone-receptor-positive, HER2-negativ…